Literature DB >> 11042307

Vascular endothelial growth factor and prognosis of cervical carcinoma.

W F Cheng1, C A Chen, C N Lee, L H Wei, F J Hsieh, C Y Hsieh.   

Abstract

OBJECTIVE: To evaluate vascular endothelial growth factor (VEGF) as a marker for predicting lymph node metastasis and an independent prognostic factor of early-stage cervical carcinoma.
METHODS: One hundred thirty-five women with stage IB-IIA cervical carcinoma had radical abdominal hysterectomies and pelvic lymph node dissections. Intratumoral cytosol VEGF concentrations were assayed with enzyme immunoassay. Histopathologic items and cytosol VEGF-influencing clinical outcomes were compared.
RESULTS: Twenty-two women (16.3%) who had disease recurrence had higher levels of cytosol VEGF (1020 versus 112 pg/mg protein, P <.001) than those without recurrence. Using a cutoff value of 400 pg/mg protein resulted in best sensitivity of 75%, best specificity of 70%, positive predictive value of 41%, and negative predictive value of 92%. Only overexpressed cytosol VEGF (hazard ratio 6.44, P <.001) was an independent prognostic factor of disease-free survival. The overexpressed cytosol VEGF (hazard ratio 4.50, P =.021) and positive lymphovascular emboli (hazard ratio 4.11, P =.045) were independent prognostic factor of overall survival.
CONCLUSION: Cytosol VEGF might be a biomarker for the status of pelvic lymph nodes in early-stage cervical carcinoma and an independent prognostic indicator of its outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11042307     DOI: 10.1016/s0029-7844(00)01025-5

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  28 in total

Review 1.  Targeting angiogenesis in advanced cervical cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

2.  Aberrant expression of VEGF-C is related to grade of cervical intraepithelial neoplasia (CIN) and high risk HPV, but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer.

Authors:  M Branca; C Giorgi; D Santini; L Di Bonito; M Ciotti; A Benedetto; P Paba; S Costa; D Bonifacio; P Di Bonito; L Accardi; C Favalli; K Syrjänen
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

Review 3.  Molecular staging of gynecological cancer: What is the future?

Authors:  Pratibha S Binder; Jaime Prat; David G Mutch
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2015-03-04       Impact factor: 5.237

Review 4.  Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.

Authors:  Alexander C Cohen; Brandon M Roane; Charles A Leath
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

5.  The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus.

Authors:  Kosuke Yoshida; Shiro Suzuki; Jun Sakata; Fumi Utsumi; Kaoru Niimi; Nobuhisa Yoshikawa; Kimihiro Nishino; Kiyosumi Shibata; Fumitaka Kikkawa; Hiroaki Kajiyama
Journal:  Oncol Lett       Date:  2018-05-02       Impact factor: 2.967

6.  Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix.

Authors:  Perry W Grigsby; Robert S Malyapa; Ryuji Higashikubo; Julie K Schwarz; Michael J Welch; Phyllis C Huettner; Farrokh Dehdashti
Journal:  Mol Imaging Biol       Date:  2007 Sep-Oct       Impact factor: 3.488

Review 7.  Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

8.  Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.

Authors:  A M Jubb; T Q Pham; A M Hanby; G D Frantz; F V Peale; T D Wu; H W Koeppen; K J Hillan
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

9.  Serum vascular endothelial growth factor: a prognostic factor in cervical cancer.

Authors:  Petra L M Zusterzeel; Paul N Span; Marja G K Dijksterhuis; Chris M G Thomas; Fred C G J Sweep; Leon F A G Massuger
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-15       Impact factor: 4.553

10.  UFT and its metabolite gamma-butyrolactone (GBL) inhibit angiogenesis induced by vascular endothelial growth factor in advanced cervical carcinoma.

Authors:  Nobutaka Nagai; Keiji Mukai; Eiji Hirata; Hong Hua Jin; Masaaki Komatsu; Mayu Yunokawa
Journal:  Med Oncol       Date:  2007-10-30       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.